John Marshall Bancorp (NASDAQ:JMSB) reported quarterly earnings of $0.58 per share. This is a 7.41 percent increase over earnings of $0.54 per share from the same period last year.
Sagimet Biosciences Announces Oral Presentation Of Preclinical Results Of FASN Inhibitor In Combination With Semaglutide At The 7th Obesity And NASH Drug Development Summit
Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways, will present preclinical
